{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:42:23Z","timestamp":1790660543553,"version":"4.1.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"Background<\/jats:title>Pneumococcal conjugate vaccines (PCVs) have considerably reduced the burden of invasive pneumococcal disease (PD) worldwide. Consequently, though, there has been an increase in non-vaccine serotype-induced PD particularly at both the extremes of age. Biological E has developed a 14-valent PCV (PNEUBEVAX 14\u00ae) that includes additional serotypes 22F and 33F. PNEUBEVAX 14\u00ae was shown to be safe, immunogenic, and non-inferior to Prevenar-13\u00ae (PCV-13) when administered to infants in a pivotal phase 3 trial. In this study, the multi-dose presentation of PNEUBEVAX 14\u00ae with 2-phenoxyethanol as a preservative was assessed for safety and immunogenicity in infants.<\/jats:p><\/jats:sec>Methods<\/jats:title>This was a phase 3, single-blind, randomized, active-controlled study in 6\u20138-week-old healthy infants, conducted at three sites across India. The safety and immunogenicity of multi-dose presentation of PNEUBEVAX 14\u00ae were assessed in a 6\u201310\u201314-week dosing schedule, with 300 infants randomized to receive either PNEUBEVAX 14\u00ae or PCV-13. Safety-wise solicited local reactions and systemic events, unsolicited adverse events (AEs), serious AEs, and medically attended AEs (MAAEs) were recorded and analyzed. Immunogenicity was assessed by measuring anti-pneumococcal capsular polysaccharide (anti-PnCPS) immunoglobulin G (IgG) antibodies for all 14 serotypes, as well as cross-reactivity to serotype 6A.<\/jats:p><\/jats:sec>Findings<\/jats:title>The safety aspects of the multi-dose presentation of PNEUBEVAX 14\u00ae and PCV-13 were comparable with 23.3% of subjects having AEs in each of the two arms. There were no serious AEs, medically attended AEs, or deaths in either of the two study arms. Reported AEs were mild and solicited in nature, with injection site swelling and injection site pain being the most common AEs in both arms. The multi-dose presentation of PNEUBEVAX 14\u00ae was found to induce a robust immune response, including the new serotypes 22F and 33F. Importantly, PNEUBEVAX 14\u00ae also induced cross-reactive antibodies against serotype 6A.<\/jats:p><\/jats:sec>Interpretation<\/jats:title>The multi-dose presentation of PNEUBEVAX 14\u00ae is both safe and immunogenic when administered to 6\u20138-week-old infants in a 6\u201310\u201314-week dosing schedule. These results extend the findings of a pivotal phase 3 study of the single-dose presentation of PNEUBEVAX 14\u00ae that showed that it was safe, robustly immunogenic, and non-inferior to PCV-13 in the same age group and dosing schedule. Taken together, these data suggest that both the single-dose and multi-dose presentations of PNEUBEVAX 14\u00ae can be safely administered to infants to prevent pneumococcal disease caused by Streptococcus pneumoniae<\/jats:italic>.<\/jats:p><\/jats:sec>Clinical Trial Registration<\/jats:title>https:\/\/ctri.nic.in\/Clinicaltrials\/pmaindet2.php?EncHid=NTk0MzA=&amp;Enc=&amp;userName=<\/jats:uri>, identifier CTRI\/2021\/10\/037067.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1550227","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T11:21:43Z","timestamp":1744024903000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunogenicity and safety of a multi-human dose formulation of Biological E\u2019s 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14\u00ae) administered to 6\u20138-week-old healthy infants: a phase 3, single-blind, randomized, active-controlled study"],"prefix":"10.3389","volume":"16","author":[{"given":"Subhash","family":"Thuluva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh V.","family":"Matur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subbareddy","family":"Gunneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rammohan Reddy","family":"Mogulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Thammireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyan Kumar","family":"Peta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush","family":"Paliwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjana S.","family":"Mahantshetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh Kumar","family":"Banala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanth","family":"Siddaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/1469-0691.12461","article-title":"Pneumococcal infection in adults: burden of disease","author":"Drijkoningen","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30247-X","article-title":"Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15","volume":"6","author":"Wahl","year":"2018","journal-title":"Lancet Glob Health"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00024-15","article-title":"Pneumococcal capsules and their types: past, present, and future","volume":"28","author":"Geno","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"B4","unstructured":"ANTIBIOTIC RESISTANCE THREATS IN THE UNITED STATES\n \n \n 2019"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2021.1880328","article-title":"Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence","volume":"20","author":"Niederman","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"B6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis212","article-title":"Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells","volume":"205","author":"Clutterbuck","year":"2012","journal-title":"J Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu524","article-title":"Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality","volume":"59","author":"Harboe","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy312","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: A test-negative design","volume":"67","author":"McLaughlin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00309-10","article-title":"Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States","volume":"2","author":"Simonsen","year":"2011","journal-title":"mBio"},{"key":"B11","unstructured":"NewDrugs_CTRules_2019\n \n \n 2019"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.10.4.514-519.2003","article-title":"Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides","volume":"10","author":"Wernette","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"B13","article-title":"Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14\u2122) administered to 6\u20138 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study","volume-title":"Vaccine","author":"Matur","year":""},{"key":"B14","unstructured":"Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines\n \n \n \n 2013"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1160056","article-title":"Safety and tolerability of pneumococcal vaccines in children","volume":"15","author":"Esposito","year":"2016","journal-title":"Expert Opin Drug Safety"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.01.060","article-title":"Safety experience with heptavalent pneumococcal CRM197-conjugate vaccine (Prevenar\u00ae) since vaccine introduction","volume":"27","author":"Center","year":"2009","journal-title":"Vaccine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.08.025","article-title":"Safety of 13-valent pneumococcal conjugate vaccine in infants and children: Meta-analysis of 13 clinical trials in 9 countries","volume":"31","author":"Thompson","year":"2013","journal-title":"Vaccine"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1502525","article-title":"A 6-year safety surveillance of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in South Korea","volume":"14","author":"Lee","year":"2018","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177113","article-title":"Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis","volume":"12","author":"Borrow","year":"2017","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30052-5","article-title":"Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study","volume":"18","author":"Ladhani","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa043","article-title":"Characteristics of invasive pneumococcal disease caused by emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in england: A prospective observational cohort study, 2014\u20132018","volume":"71","author":"Amin-Chowdhury","year":"2020","journal-title":"Clin Infect Diseases"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9040738","article-title":"Serotype distribution of remaining pneumococcal meningitis in the mature PCV10\/13 period: findings from the PSERENADE project","volume":"9","author":"Garcia Quesada","year":"2021","journal-title":"Microorganisms"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.05.026","article-title":"The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage","volume":"36","author":"Ciruela","year":"2018","journal-title":"Vaccine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1483","article-title":"Nationwide trends of invasive pneumococcal disease in Spain from 2009 through 2019 in children and adults during the pneumococcal conjugate vaccine era","volume":"73","author":"de Miguel","year":"2021","journal-title":"Clin Infect Diseases"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226353","article-title":"The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017","volume":"14","author":"Hozbor","year":"2019","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.01.086","article-title":"The potential impact of PCV-13, PCV-15 and PCV-20 vaccines in Colombia","volume":"42","author":"Serrano-Mayorga","year":"2024","journal-title":"Vaccine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac475","article-title":"Distribution of serotypes causing invasive pneumococcal disease in children from high-income countries and the impact of pediatric pneumococcal vaccination","volume":"76","author":"Grant","year":"2023","journal-title":"Clin Infect Diseases"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.03.065","article-title":"Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: An active prospective nationwide surveillance","volume":"32","author":"Ben-Shimol","year":"2014","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9050396","article-title":"Department of Public Health tM. Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts","volume":"9","author":"Lapidot","year":"2020","journal-title":"Pathogens"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2023.2294153","article-title":"PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children","volume":"23","author":"Chapman","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.06.056","article-title":"The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A","volume":"29","author":"Cooper","year":"2011","journal-title":"Vaccine"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30735-0","article-title":"Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial","volume":"21","author":"Clarke","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1086\/jid.1999.180.issue-5","article-title":"Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants","volume":"180","author":"Yu","year":"1999","journal-title":"J Infect Dis"},{"key":"B34","article-title":"Single-dose versus multi-dose vaccine vials for immunization programmes in developing countries","volume":"81","author":"Drain","year":"2003","journal-title":"Bull World Health Organ"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1550227\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T11:22:01Z","timestamp":1744024921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1550227\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2025.1550227"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1550227","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"article-number":"1550227"}}